# Gemcitabine Hydrochloride and Cisplatin or High-Dose Methotrexate, Vinblastine, Doxorubicin Hydrochloride, and Cisplatin in Treating Patients With Urothelial Cancer

> **NCT01639521** · PHASE2 · WITHDRAWN · sponsor: **University of Southern California**

## Conditions studied

- Anterior Urethral Cancer
- Localized Transitional Cell Cancer of the Renal Pelvis and Ureter
- Posterior Urethral Cancer
- Recurrent Bladder Cancer
- Recurrent Urethral Cancer
- Regional Transitional Cell Cancer of the Renal Pelvis and Ureter
- Stage III Bladder Cancer
- Transitional Cell Carcinoma of the Bladder
- Ureter Cancer
- Urethral Cancer Associated With Invasive Bladder Cancer

## Interventions

- **DRUG:** cisplatin
- **DRUG:** gemcitabine hydrochloride
- **DRUG:** methotrexate
- **DRUG:** vinblastine
- **DRUG:** doxorubicin hydrochloride
- **BIOLOGICAL:** pegfilgrastim
- **OTHER:** laboratory biomarker analysis

## Key facts

- **NCT ID:** NCT01639521
- **Lead sponsor:** University of Southern California
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2013-05
- **Primary completion:** 2013-05
- **Final completion:** 2013-05
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Lack of funding
- **Last updated:** 2014-01-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01639521

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01639521, "Gemcitabine Hydrochloride and Cisplatin or High-Dose Methotrexate, Vinblastine, Doxorubicin Hydrochloride, and Cisplatin in Treating Patients With Urothelial Cancer". Retrieved via AI Analytics 2026-07-07 from https://api.ai-analytics.org/clinical/NCT01639521. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*